COST-EFFECTIVENESS OF ATORVASTATIN VERSUS SIMVASTATIN IN PREVENTION OF CARDIOVASCULAR EVENTS FROM A THAILAND SOCIETAL PERSPECTIVE

被引：0
|
作者：
Sukonthasarn, A. [1 ]
Thongtang, N. [2 ]
Ektare, V [3 ]
Du, F. [4 ]
Brizuela, G. [5 ]
Rustagi, S. [6 ]
Gao, X. [7 ]
机构：
[1] Bangkok Hosp Chiang Mai, Bangkok, Thailand
[2] Mahidol Univ, Fac Med, Siriraj Hosp, Bangkok, Thailand
[3] Pharmerit India Private Ltd, Andheri East, MH, India
[4] Pharmerit Shanghai Co Ltd, Shanghai 31, Peoples R China
[5] A Viatris Co, Antipolo, Philippines
[6] A Viatris Co, Bangkok, Thailand
[7] Pharmerit, Waban, MA USA
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV21
引用
收藏
页码：S70 / S70
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health care perspective
    Aosta-Scharplatz, M.
    Beamer, B.
    Frial, T.
    Gandhi, S. K.
    VALUE IN HEALTH, 2007, 10 (06) : A221 - A221
  • [2] COST-EFFECTIVENESS ANALYSIS OF ATORVASTATIN COMPARED TO SIMVASTATIN IN THE PREVENTION OF CARDIOVASCULAR DISEASES IN THE CZECH REPUBLIC
    Klimes, J.
    Vocelka, M.
    Dolezal, T.
    Kruntoradova, K.
    VALUE IN HEALTH, 2013, 16 (07) : A528 - A528
  • [3] Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective
    Costa-Scharplatz, Madlaina
    Ramanathan, Krishnan
    Frial, Tony
    Bearner, Bruce
    Gandhi, Sanjay
    CLINICAL THERAPEUTICS, 2008, 30 (07) : 1345 - 1357
  • [4] Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: A French adaptation of CARDS
    Lafuma, Antoine
    Colin, Xavier
    Solesse, Anne
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2008, 101 (05) : 327 - 332
  • [5] Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events
    Gandhi, Sanjay K.
    Jensen, Marie M.
    Fox, Kathleen M.
    Smolen, Lee
    Olsson, Anders G.
    Paulsson, Thomas
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2012, 4 : 1 - 11
  • [6] Cost-effectiveness of atorvastatin compared to simvastatin in the Netherlands
    Severens, JL
    Prins, MH
    Monteban, HC
    VALUE IN HEALTH, 2003, 6 (06) : 671 - 671
  • [7] Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain
    Cosin Sales, Juan
    Fuentes Jimenez, Francisco Jose
    Mantilla Morato, Teresa
    Ruiz, Emilio
    Becerra, Virginia
    Aceituno, Susana
    Giovanna Ferrario, Maria
    Lizan, Luis
    Gracia, Alfredo
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2015, 27 (05): : 228 - 238
  • [8] Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events
    Sehested, Thomas S. G.
    Bjerre, Jenny
    Ku, Seul
    Chang, Andrew
    Jahansouz, Alison
    Owens, Douglas K.
    Hlatky, Mark A.
    Goldhaber-Fiebert, Jeremy D.
    JAMA CARDIOLOGY, 2019, 4 (02) : 128 - 135
  • [9] Cost-Effectiveness of Canakinumab From a Canadian Perspective for Recurrent Cardiovascular Events
    Boczar, Kevin E.
    Beanlands, Rob
    Wells, George
    Coyle, Doug
    CJC OPEN, 2022, 4 (05) : 441 - 448
  • [10] COST-EFFECTIVENESS OF FREMANEZUMAB FROM A SOCIETAL PERSPECTIVE IN ENGLAND
    Skroumpelos, A.
    Freddi, M.
    Akcicek, H.
    Cohen, J. M.
    Driessen, M. T.
    VALUE IN HEALTH, 2021, 24 : S162 - S163
12345